期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 10, 页码 4454-4471出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI96138
关键词
-
资金
- Wellcome investigators [107849/Z/15/Z]
- MRC project [MR/P011853/1]
- MRC programme [MR/P023576/1]
- MRC CASE studentship
- University of Manchester Stepping Stones fellowship
- University of Leeds Academic Fellowship
- MRC Clinical Research Training Fellowship [MR/N021479/1]
- Wellcome Trust [107849/Z/15/Z] Funding Source: Wellcome Trust
- BBSRC [BB/I018654/1] Funding Source: UKRI
- MRC [MR/P023576/1, MR/M008908/1, MR/P011853/1, MR/P00279X/1, MR/N002024/1, MR/N021479/1, MR/P011853/2] Funding Source: UKRI
The glucocorticoid receptor (GR) is a major drug target in inflammatory disease. However, chronic glucocorticoid (GC) treatment leads to disordered energy metabolism, including increased weight gain, adiposity, and hepatosteatosis - all programs modulated by the circadian clock. We demonstrated that while antiinflammatory GC actions were maintained irrespective of dosing time, the liver was significantly more GC sensitive during the day. Temporal segregation of GC action was underpinned by a physical interaction of GR with the circadian transcription factor REVERBa and co-binding with liver-specific hepatocyte nuclear transcription factors (HNFs) on chromatin. REVERBa promoted efficient GR recruitment to chromatin during the day, acting in part by maintaining histone acetylation, with REVERBa-dependent GC responses providing segregation of carbohydrate and lipid metabolism. Importantly, deletion of Reverba inverted circadian liver GC sensitivity and protected mice from hepatosteatosis induced by chronic GC administration. Our results reveal a mechanism by which the circadian clock acts through REVERBa in liver on elements bound by HNF4A/HNF6 to direct GR action on energy metabolism.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据